ARVN - Arvinas Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

97.91M

Cash

1.124B

Avg Qtr Burn

-76.9M

Short % of Float

8.16%

Insider Ownership

9.52%

Institutional Own.

96.51%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bavdegalutamide (ARV-110) (PROTAC protein degrader) Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-471 (oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-766 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.